-
The National Institute of Standards and Technology (NIST) released publication SP 800-66 Revision 1, An Introductory Resource Guide for Implementing the Health Insurance Portability and Accountability Act Security Rule, on Oct. 24.
-
-
In a retrospective review of hematopoietic stem cell transplantation for pre-treated patients with chronic lymphocytic leukemia, who have 17p deletion, three-year overall and progression-free survival were 44% and 37%, respectively. This matches favorably when compared to patients with the same chromosomal abnormality treated with chemotherapy alone.
-
Recent studies have suggested that multiple myeloma and monoclonal gammopathy of unknown significance (MGUS) may predispose to venous thromboembolism, even in untreated patients.
-
Low PSA levels do not assure the absence of prostate cancer.
-
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
-
For young males cured of Hodgkin's Lymphoma, infertility is a significant issue.
-
The dramatic reduction in in-stent restenosis (ISR) afforded by drug-eluting stents (DES) led to their widespread use throughout the world. Subsequently, more patients and lesions could be treated percutaneously with less thought about ISR. With the advent of a more widespread adoption of percutaneous coronary intervention, registry data began suggesting an increased risk of late and very late stent thrombosis with DES compared to bare-metal stents (BMS).
